Inflammasome Therapeutics’ Kamuvudine K8 Reduces Geographic Atrophy Lesion Growth by 54% in Phase 2 Study

Phase 2 data for kamuvudine K8, an investigational inflammasome-directed treatment from Inflammasome Therapeutics, were presented during Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting. The 0.7 mg dose was associated with a 54% reduction in geographic atrophy (GA) lesion growth over six months compared with untreated fellow eyes. The study enrolled 30 participants and was not powered to demonstrate a visual-acuity benefit.

Phase 2 Study Design

• Developer: Inflammasome Therapeutics.
• Presentation: Retina Subspecialty Day, AAO 2026 Annual Meeting.
• Population: 30 people with bilateral GA secondary to dry age-related macular degeneration (AMD).
• Treatment: Bioerodible intravitreal implant, administered to the worse-seeing eye at baseline and month three.
• Control: The untreated fellow eye.
• Duration: Six months.
• Key result: 54% lower lesion growth with the 0.7 mg dose.
• Exploratory finding: A four-letter visual-acuity advantage in a non-subfoveal subgroup.
• Safety: No drug-related serious adverse events reported through six months.

The paired-eye design controls for some patient-level factors, but the two eyes can differ at baseline and need not progress at the same rate. Six months is a short period for a disease measured by progressive lesion enlargement.

How Kamuvudine K8 Works

K8 inhibits inflammasome-related inflammatory activity, which may contribute to retinal pigment epithelium (RPE) damage and progressive GA. Complement inhibitors act on components of the complement cascade; inflammasome inhibition addresses a separate biological pathway. This distinction is relevant as researchers investigate the multiple mechanisms involved in dry AMD progression.

Interpreting Structural Results

GA is characterized by progressive loss of RPE cells and photoreceptors. Trials often measure lesion size because structural progression can be quantified on retinal imaging. Slowing lesion enlargement is clinically meaningful, yet it does not necessarily translate into better visual acuity. Patient-relevant outcomes, including reading, low-luminance function and time until foveal involvement, should accompany lesion-area results.

Next Steps for Development

A robust Phase 3 program will need masked grading of fundus autofluorescence, prespecified handling of baseline lesion size and location, and follow-up long enough to show whether the relative effect persists and translates into functional benefit.

Quarterly implantation could reduce visit burden compared with more frequent injections. The 24-gauge delivery system and repeat implantation bring their own procedural considerations, and larger, longer studies are needed to characterize inflammation, infection, pressure changes and other injection-related harms. Retreatment requirements and durability will also shape development. The next decision point is an adequately powered controlled study; comparison with approved GA drugs would be premature.

Conclusion

The 54% lesion-growth signal warrants a larger controlled study, particularly because it comes from 30 participants and a six-month fellow-eye comparison. The inflammasome-directed mechanism adds a distinct pathway to GA research. Functional benefit and the safety of repeated implantation remain open questions.

The post Inflammasome Therapeutics’ Kamuvudine K8 Reduces Geographic Atrophy Lesion Growth by 54% in Phase 2 Study appeared first on Ophthalmology Breaking News.

Source: ophthalmologybreakingnews.com
Author: OBN Editorial Team | Date: 2026-10-09 09:00:00